Advertisement

One course versus two courses of recombinant alpha interferon in chronic C hepatitis

  • Gloria Taliani
  • C. Furlan
  • F. Grimaldi
  • C. Clementi
  • R. Lecce
  • M. Manganaro
  • F. Duca
  • Carlo De Bac
Part of the Archives of Virology book series (ARCHIVES SUPPL, volume 4)

Summary

Fifty-five patients with antibodies to HCV and chronic liver disease have been enrolled in the study. Thirty-four patients were treated with recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months), and were compared to 21 untreated controls.

Alanine aminotransferase (ALT) normalization was observed in a significant proportion of treated patients (52.9%), but 66.6% of them experienced a relapse after discontinuation of the therapy. The evaluation of the early ALT behavior after the 10 days priming with daily IFN administration was useful in predicting the response.

The administration of a second IFN course with the same schedule and duration as the first course did not increase the efficacy of the treatment. Increased dosage and/or prolonged administration are probably required.

Keywords

Biochemical Remission Recombinant Immunoblot Assay Active Cirrhosis Recombinant Human Alpha Interferon Recombinant Interferon Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506–1510PubMedCrossRefGoogle Scholar
  2. 2.
    Davis GL, Baiart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506PubMedCrossRefGoogle Scholar
  3. 3.
    Saracco G, Rosina F, Torrani Cerenzia MR et al (1990) A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 11 [Suppl]: 43–49CrossRefGoogle Scholar
  4. 4.
    Ferenci P, Vogel W, Pristautz H et al (1990) One-year treatment of chronic non-A, non-B hepatitis with interferon alfa 2b. J Hepatol 11 [Suppl]: 50–53CrossRefGoogle Scholar
  5. 5.
    Jacyna MR, Brooks MG, Loke RHT et al (1989) Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 298: 80–82CrossRefGoogle Scholar
  6. 6.
    Hoofnagle JH, Mullen KD, Jones DB et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315: 1575–1578PubMedCrossRefGoogle Scholar
  7. 7.
    Gomez-Rubio M, Porres JC, Castillo I et al (1990) Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 11 [Suppl]: 63–67CrossRefGoogle Scholar
  8. 8.
    Taliani G, Lecce R, Clementi C, Furlan C, De Bac C (1991) Antibodies to hepatitis C virus and response to Interferon treatment in non-A, non-B chronic hepatitis. J Hepatol 12: 264–265PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Gloria Taliani
    • 1
    • 2
  • C. Furlan
    • 1
  • F. Grimaldi
    • 1
  • C. Clementi
    • 1
  • R. Lecce
    • 1
  • M. Manganaro
    • 1
  • F. Duca
    • 1
  • Carlo De Bac
    • 1
  1. 1.Institute of Tropical and Infectious Diseases“La Sapienza” UniversityRomeItaly
  2. 2.Department of Tropical Diseases“La Sapienza” UniversityRomeItaly

Personalised recommendations